Based on this information and the fact that MTH1 has been characterized as a non-essential protein in normal cells within a realistic treatment window39, we hypothesized that patients with B-cell lymphoma could possibly benefit from inhibition of MTH1. This evidence concerns the gene NUDT1 and B-cell non-Hodgkin lymphoma.